Back

CA inhibitor 1 treatment has only transient effects on estrous cyclicity in mice

Giacometti, L. L.; Dalere, D. M.; Lwamba, B.; Goldberg, S. L.; Feliciano, K.; Barker, J. M.

2026-01-13 neuroscience
10.64898/2026.01.12.699062 bioRxiv
Show abstract

Approximately 45% of new HIV infections worldwide occur in women and girls and adherence to pre-exposure prophylaxis (PrEP) to prevent HIV infection is limited. Long-acting PrEP such as lenacapavir may improve adherence. One barrier to PrEP usage in women and girls is impact on the menstrual cycle, though impacts of long-acting PrEP are unclear. To model the effect of lenacapavir administration on cyclicity, adult female C57Bl/6J mice were injected with CA inhibitor 1 and assessed for estrous cyclicity. Ca inhibitor 1 transiently delayed the start of the next cycle. However, Ca inhibitor 1 was associated with a higher proportion of normal length estrous cycles. Ca inhibitor 1 did not impact astrocyte immunoreactivity or chronic cellular activity in the medial preoptic area (mPOA), a major regulator of the estrous cycle. These findings suggest that lenacapavir may be a viable PrEP alternative for those concerned with PrEP impacts on menstrual cycle.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.